Tags

Type your tag names separated by a space and hit enter

Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
SLAS Discov. 2020 Dec; 25(10):1097-1107.SD

Abstract

SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019. Since then, the virus has stretched its grip to almost all the countries in the world, affecting millions of people and causing enormous casualties. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2019. As of June 12, 2020, almost 7.30 million people have already been infected globally, with 413,000 reported casualties. In the United States alone, 2.06 million people have been infected and 115,000 have succumbed to this pandemic. A multipronged approach has been launched toward combating this pandemic, with the main focus on exhaustive screening, developing efficacious therapies, and vaccines for long-term immunity. Several pharmaceutical companies in collaboration with various academic institutions and governmental organizations have started investigating new therapeutics and repurposing approved drugs so as to find fast and affordable treatments against this disease. The present communication is aimed at highlighting the efforts that are currently underway to treat or prevent SARS-CoV-2 infection, with details on the science, clinical status, and timeline for selected investigational drugs and vaccines. This article is going to be of immense help to the scientific community and researchers as it brings forth all the necessary clinical information of the most-talked-about therapeutics against SARS-CoV-2. All the details pertaining to the clinical status of each therapeutic candidate have been updated as of June 12, 2020.

Authors+Show Affiliations

Department of Chemistry and Biochemistry, Auburn University, Auburn, Alabama, USA. Department of Chemistry, Islamia College of Science and Commerce, Srinagar, Jammu and Kashmir, India.Department of Chemistry, Islamia College of Science and Commerce, Srinagar, Jammu and Kashmir, India.Government Medical College, Karan Nagar, Srinagar, Jammu and Kashmir, India.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32692266

Citation

Banday, Abid H., et al. "Potential Repurposed Therapeutics and New Vaccines Against COVID-19 and Their Clinical Status." SLAS Discovery : Advancing Life Sciences R & D, vol. 25, no. 10, 2020, pp. 1097-1107.
Banday AH, Shameem SA, Ajaz SJ. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. SLAS Discov. 2020;25(10):1097-1107.
Banday, A. H., Shameem, S. A., & Ajaz, S. J. (2020). Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. SLAS Discovery : Advancing Life Sciences R & D, 25(10), 1097-1107. https://doi.org/10.1177/2472555220945281
Banday AH, Shameem SA, Ajaz SJ. Potential Repurposed Therapeutics and New Vaccines Against COVID-19 and Their Clinical Status. SLAS Discov. 2020;25(10):1097-1107. PubMed PMID: 32692266.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. AU - Banday,Abid H, AU - Shameem,Shameem A, AU - Ajaz,Sheikh J, Y1 - 2020/07/21/ PY - 2020/7/22/pubmed PY - 2020/12/15/medline PY - 2020/7/22/entrez KW - COVID-19 KW - SARS-CoV-2 KW - monoclonal antibodies KW - repurposed therapeutics KW - vaccines SP - 1097 EP - 1107 JF - SLAS discovery : advancing life sciences R & D JO - SLAS Discov VL - 25 IS - 10 N2 - SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was first reported in Wuhan, China, in December 2019. Since then, the virus has stretched its grip to almost all the countries in the world, affecting millions of people and causing enormous casualties. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2019. As of June 12, 2020, almost 7.30 million people have already been infected globally, with 413,000 reported casualties. In the United States alone, 2.06 million people have been infected and 115,000 have succumbed to this pandemic. A multipronged approach has been launched toward combating this pandemic, with the main focus on exhaustive screening, developing efficacious therapies, and vaccines for long-term immunity. Several pharmaceutical companies in collaboration with various academic institutions and governmental organizations have started investigating new therapeutics and repurposing approved drugs so as to find fast and affordable treatments against this disease. The present communication is aimed at highlighting the efforts that are currently underway to treat or prevent SARS-CoV-2 infection, with details on the science, clinical status, and timeline for selected investigational drugs and vaccines. This article is going to be of immense help to the scientific community and researchers as it brings forth all the necessary clinical information of the most-talked-about therapeutics against SARS-CoV-2. All the details pertaining to the clinical status of each therapeutic candidate have been updated as of June 12, 2020. SN - 2472-5560 UR - https://www.unboundmedicine.com/medline/citation/32692266/Potential_Repurposed_Therapeutics_and_New_Vaccines_against_COVID_19_and_Their_Clinical_Status_ DB - PRIME DP - Unbound Medicine ER -